Abstract: Described is a method of decreasing the weight in mammals to a desired level comprising orally administering thereto an effective weight reducing amount of a non-toxic anion exchange resin containing composition for a desired period of time to achieve a desired weight reduction. Compositions useful for reducing weight in patients contain an anion exchange resin such as cholestyramine, colestipol or polidexide, with bran and optionally, artificial sweeteners and flavors.

Abstract: Sustained and enhanced antipyretic response is elicited in a mammalian organism in need of such treatment, i.e., a mammal suffering from elevated body temperature (fever), by administering thereto a unit dosage sustainedly enhancing, antipyretically effective amount of the free acid S(+) flurbiprofen enantiomer, said enantiomer being substantially free of its R(-) flurbiprofen antipode.

Abstract: Disclosed are fluorocarbon emulsions comprising amino acids and substances related to amino acids, such as substituted amino acids or amphoteric groups of amino acid side chains, for example, the imidazolyl group of histidine. Emulsion formulations comprising imidazole and imidazole based drugs possess anti-inflammatory and antipyretic properties which counteract transient inflammatory responses which occur when these emulsions are administered in vivo. Lipid constituents of histidine-containing emulsions are protected against oxidation caused by free radical formation.Disclosed also are emulsion formulations buffered with amino acids comprising histidine, imidazole, and related compounds that have a buffering capacity sufficient to maintain the emulsion pH within a specified range under storage conditions and protect these emulsions from the endogenous production of acid.

Abstract: An oxygen scavenging composition for use with foods, cosmetics, and pharmaceuticals comprising a combination of a metal that can exist in two redox states at ambient conditions, and a radical oxygen scavenger. The oxygen scavenging system is also effective in inhibiting the growth of yeasts, molds, and most aerobic bacteria.

Abstract: This invention pertains to a method for treating a subject for Tardive Dyskinesia by administering a dopaminergic agent to the subject such that the dopaminergic agent enters the brain or by administering a prodrug of a therapeutic agent. The dopaminergic agent preferably is 2 prodrug formed by coupling dopamine to a fatty acid. This invention further pertains to methods of providing pharmaceutical preparations and packaged pharmaceuticals for Tardive Dyskinesia.

Abstract: New organic nitrate compounds, formed by condensing a nitrato alkanoic acid with a sulfur-containing amino acid or peptide followed by the reaction of the resulting product with an amino acid, N-acylamino acid, peptide or an N-acyl peptide to produce a thio ester thereof, which prevent nitrate tolerance or overcome existing tolerance and which are useful for the treatment of cardiac diseases including circulatory diseases, coronary dilation, high blood pressure, cardiac insufficiency and for dilating the peripheral vessels.

Abstract: 3,5-Dihalogeno-1,2,6-thiadiazin-4-ones of the formula ##STR1## in which R.sub.1 and R.sub.2 independently of one another are chlorine, fluorine or bromine, in particular 3,5-dichloro-1,2,6-thiadiazin-4-one, are excellently suitable for use as biocides for the protection of industrial materials and for water systems, for example for wood, plastics, paints, oils, adhesives and industrial water circulation systems.

Abstract: The invention discloses certain heterocyclic, thioether, keto-ester and alkyl phospholipids, e.g., heterocyclic phospholipids having the formula ##STR1## where R is n-C.sub.14 -C.sub.20 alkyl or O-n-C.sub.14 -C.sub.20 alkyl; each R.sub.1 is methyl or ethyl; n is 2-6; and X is --CH.sub.2 --m, where m is 2-4, CH.sub.2 CH.sub.2 O or CH.sub.2 CH.sub.2 S, or a corresponding hydrate thereof, which compounds are useful in treating multiple sclerosis.

Abstract: A procaine acid addition salt, wherein the acid is attached to the diethylamino nitrogen, is complexed with a biologically active organic acid such as a vitamin acid, essential unsaturated fatty acid, C.sub.4 to C.sub.6 hydroxycarboxylic acid or alpha amino acid in stoichiometric ratios of organic acid to procaine acid addition salt to form a double salt complex wherein the organic acid attaches to the p-amino nitrogen. Such double salt complexes protect the procaine molecule from cholinesterase hydrolysis when orally administered to warm blooded animals allowing the complex to be carried intact to the site of damaged cells and across the cell membrane where the double salt complex is disassociated in the cell releasing the organic acid and procaine for cellular repair and regeneration. Procaine hydrochloride is the preferred procaine salt. Preferred acids are citric and vitamin acids including nicotinic acid, ascorbic acid, biotin and folic acid.

Abstract: Disclosed is a method for preventing the transmission of an ectoparasite-borne pathogen to a mammal exposed to predation by the ectoparasite, wherein a time delay exists between attachment of the ectoparasite to the mammal and transmission of the pathogen from the ectoparasite to the mammal. The method comprises applying to the mammal an ectoparacide to kill the ectoparasite in place on the mammal, without necessarily finding or mechanically detaching the ectoparasite, at a time after the exposure of the mammal to the ectoparasite, and within the time delay, thereby preventing transmission of the pathogen from the ectoparasite to the mammal.

Abstract: A method for administering pyruvate is disclosed which comprises administering a therapeutically effective amount of a pyruvate precursor to a mammal in the form of pyruvamide or a pyruvyl-amino acid. The pyruvyl-amino acid is preferably selected from the group comprising pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvylphenyl al anine, pyruvyl-proline and pyruvyl-sarcosine, and their amides and esters as well as their salts. Associated with the administration of a pyruvate precursor to a mammal in accordance with this invention are improved insulin resistance, lower fasting insulin levels, and reduced fat gain. Novel methods of synthesizing several pyruvate precursors are also disclosed.

Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.

Abstract: An euthanasia solution based upon gamma-hydroxybutramide and a cardiotoxic amount of a compound selected from chloroquine and quinacrine is described. The composition provides effective euthanasia without unwanted side effects.

Abstract: Methods and pharmaceutical formulations of alpha.sub.2 agonists and alpha.sub.3 antagonists which are useful in lowering intraocular pressure (IOP) and treatment of intraocular hypertension. Co-administration of a therapeutic amount of alpha.sub.2 agonist with a potentiating amount of alpha.sub.3 agonist is effective in lowering IOP and treatment of intraocular hypertension.

Abstract: An ovulation inhibiting preparation for hormonal contraception, comprising two hormone constituents packed spatially separate in a packing unit intended for chronological, sequential oral administration, said constituents each comprising a plurality of daily hormone units accommodated spatially separate and individually removable in the packaging unit. The first hormone constituent consists essentially of an estrogen preparation which effects a disturbance of the follicle stimulation; the second hormone constituent consists of an estrogen preparation and a gestagen preparation in a dose at least adequate for inhibiting ovulation. The total number of daily hormone units is equal to the total number of days in the desired cycle, and the number of daily units of the first hormone constituent is less than the number of daily units of the second hormone constituent. The first hormone constituent comprises 5 to 14 daily units, and the second hormone constituent comprises 23 to 14 daily units.

Abstract: The subject invention involves compositions comprising 4-(3,5-bis(1,1-dimethylethyl-4-hydroxyphenyl)-4-oxobutanamide, or 4-(3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl)-4-oxobutanoic acid and pharmaceutically-acceptable salts thereof, and a pharmaceutically-acceptable carrier. The subject invention also involves methods for treating diseases characterized by inflammation and/or pain, such as rheumatoid arthritis and osteoarthritis, in humans or lower animals by administration of a safe and effective amount of this compound to the human or lower animal in need of such treatment.

Abstract: Novel precipitated silicon dioxide abrasive compositions which can be incorporated into therapeutic toothpaste compositions containing soluble fluoride salts are disclosed. The abrasives comprise low structure, high fluoride compatible amorphous precipitated silicon dioxides (silicas) having a controlled refractive index for use in low water clear gel dentifrice applications. Also provided are methods for preparation of the novel silicon dioxide abrasives and resulting toothpaste formulations containing such abrasives.

Abstract: Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-me thoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

Abstract: A method of treating human skin to enhance the ability of skin in the absorption and retention of moisture in order to retard skin moisture loss. There is applied to skin an organosilicon compound exhibiting humectant-like characteristics which is a carboxylic acid salt functional polysiloxane. An alternate method treats human skin to reduce the transepidermal water loss of skin in order to enhance skin softness. There is applied to skin an occlusive film forming organosilicon compound which is a carboxyfunctional polysiloxane or its metal carboxylate salt.

Abstract: A method is provided for prevention and treatment of cardiovascular disease, such as atherosclerosis, by administering therapeutically effective dosages of a drug comprised of ascorbate, lipoprotein(a) binding inhibitors, and antioxidants.